Latest news with #AptarGroup
Business Wire
31-07-2025
- Business
- Business Wire
Aptar Reports Second Quarter 2025 Results
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported the following second quarter results for the period ended June 30, 2025, as compared to the corresponding period of the last fiscal year. Second Quarter 2025 Highlights (compared to the prior year quarter) Reported sales increased 6% and core sales increased 3% Reported net income increased 24% to $112 million and adjusted EBITDA increased 13% from the prior year to $218 million Reported earnings per share increased 25% to $1.67 and adjusted earnings per share increased 18% to $1.66 Achieved an adjusted EBITDA margin of 22.6% an increase of 140 basis points Returned $100 million to shareholders through share repurchases and dividends Six Months Year-to-Date 2025 Highlights (compared to the prior year period) Reported and core sales grew 2% Reported net income increased 10% to $191 million and adjusted EBITDA increased 8% to $402 million Reported earnings per share increased 10% to $2.83 and adjusted earnings per share increased 8% to $2.86 Returned $210 million to shareholders through share repurchases and dividends 'Each of our segments contributed positively to our second quarter results and each expanded their adjusted EBITDA margins. Our Pharma and Closures segments drove the growth through increased volumes and sales of higher value products. We also returned $100 million to shareholders through dividends and share repurchases in the quarter, bringing the total to $210 million in the first half of the year,' said Stephan B. Tanda, Aptar President and CEO. Second Quarter Results For the quarter ended June 30, 2025, reported sales increased 6% to $966 million compared to $910 million in the prior year and core sales increased 3%. Second Quarter Segment Sales Analysis (Change Over Prior Year) Aptar Pharma Aptar Beauty Aptar Closures Total AptarGroup Reported Sales Growth 7% 4% 8% 6% Currency Effects (1) (4)% (2)% (1)% (3)% Acquisitions 0% (1)% 0% 0% Core Sales Growth 3% 1% 7% 3% (1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates. Expand Aptar Pharma's reported sales increased 7% and core sales increased 3% in the quarter when compared to the prior year period. The segment's positive results were driven by strong demand in Prescription, Injectables and Active Material Science divisions, while Consumer Healthcare declined. Demand continued for proprietary drug delivery systems used for emergency medicines, as well as asthma, COPD and ophthalmic treatments. Injectables core sales grew 9% due to increased demand for higher value elastomeric components, which are used in a number of end markets including biologics and GLP-1. Active Material Science core sales grew 11%, due to higher demand from active film solutions. Adjusted EBITDA margins grew 130 basis points in the quarter, with royalty revenues helping drive adjusted EBITDA margins to 35.4%. Aptar Beauty's reported sales increased 4% and core sales were up 1% compared to the prior year quarter primarily due to higher tooling sales for the personal care and beauty end markets. In the quarter, personal care products continued to show strong growth but could not offset lower demand in beauty dispensing technologies for fragrance and for full pack solutions. The pace of new fragrance launches remained subdued due to tariff-related uncertainties. In China, the beauty market continued to improve, with healthy sales in the quarter for dispensing systems, mainly due to demand from regional customers. Adjusted EBITDA margins increased by 20 basis points, to 14.1%. Aptar Closures' reported sales increased 8% from the prior year quarter and core sales increased 7%. The solid product sales growth was mainly driven by increased demand in the food and beverage end markets. The segment experienced growth in almost every region, across a number of applications including sauces, salad dressings and functional drinks. Adjusted EBITDA margins improved to 16.9%, expanding by 130 basis points. Aptar reported second quarter earnings per share of $1.67 compared to $1.34 reported a year ago. Adjusted earnings per share, excluding restructuring charges, acquisition costs, and the unrealized gains or losses on an equity investment, were $1.66 compared to the prior year period's adjusted earnings per share of $1.41, including comparable exchange rates. The second quarter effective tax rate was 20.0% compared to the prior year period's effective tax rate of 23.5%. The lower effective tax rate for the three months ended June 30, 2025 was due to an expected tax benefit as part of the company's ongoing tax planning, and greater tax benefits from share-based compensation. Actual exchange and effective tax rates for the second quarter were comparable to the guidance provided by the company. Six Months Year-To-Date Results For the six months ended June 30, 2025, reported sales increased 2% to $1.85 billion compared to $1.83 billion in the prior year. Core sales also increased 2%. Six Months Year-To-Date Segment Sales Analysis (Change Over Prior Year) Aptar Pharma Aptar Beauty Aptar Closures Total AptarGroup Total Reported Sales Growth 4% (1)% 2% 2% Currency Effects (1) (1)% 0% 1% 0% Acquisitions 0% 0% 0% 0% Core Sales Growth 3% (1)% 3% 2% (1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates. Expand For the six months ended June 30, 2025, Aptar's reported earnings per share were $2.83, an increase of 10%, compared to $2.57 reported a year ago. For the first six months of the year, adjusted earnings per share, excluding restructuring charges, acquisition costs, and the unrealized gains or losses on an equity investment, were $2.86 and increased 8% from prior year adjusted earnings per share of $2.64, including comparable exchange rates. The current year had an effective tax rate of 22.5% compared to the prior year effective tax rate of 22.1%. Outlook Regarding Aptar's outlook, Tanda stated, 'Looking ahead to Q3, we expect a solid quarter with continued strength in Pharma, particularly in Injectables, driven by rising demand for higher value elastomeric components fueled by growth in biologics, GLP-1 therapies, and Annex 1 compliance requirements. We anticipate challenges as naloxone sales begin to normalize after a period of rapid growth. Additionally, we expect elevated levels of cough and cold inventory in Europe to persist through the quarter. We anticipate modest Q3 contributions from our Closures and Beauty segments. Across all segments, we remain focused on cost discipline. In the face of external headwinds, our pipeline and industrialized capabilities position us well for sustained growth.' Aptar currently expects earnings per share for the third quarter of 2025, excluding any restructuring expenses, changes in the fair value of equity investments and acquisition costs, to be in the range of $1.53 to $1.61, which includes approximately 6 to 7 cents of higher legal fees associated with litigating pharma intellectual property rights. This guidance is based on an effective tax rate range of 20.5% to 22.5%, primarily due to a one-time tax benefit, with a comparable adjusted prior year effective tax rate of 23.8%. The earnings per share guidance range is based on current spot rates and a 1.15 Euro to USD exchange rate. Cash Dividends and Share Repurchases As previously announced, Aptar's Board of Directors approved a quarterly cash dividend of $0.45 per share. The payment date is August 14, 2025, to stockholders of record as of July 24, 2025. During the second quarter, Aptar repurchased 452 thousand shares for $70 million. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions. Open Conference Call There will be a conference call held on Friday, August 1, 2025 at 8:00 a.m. Central Time to discuss the company's second quarter results for 2025. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investor Relations website at Replay of the conference call can also be accessed for a limited time on the Investor Relations page of the website. About Aptar Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world's leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has more than 13,000 dedicated employees in 20 countries. For more information, visit Presentation of Non-GAAP Information This press release refers to certain non-GAAP financial measures, including current year adjusted earnings per share and adjusted EBITDA, which exclude the impact of restructuring initiatives, acquisition-related costs, certain purchase accounting adjustments related to acquisitions and investments and net unrealized investment gains and losses related to observable market price changes on equity securities. Core sales and adjusted earnings per share also neutralize the impact of foreign currency translation effects when comparing current results to the prior year. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. Adjusted EBITDA margin is adjusted EBITDA divided by reported net sales. Non-GAAP financial measures may not be comparable to similarly titled non-GAAP financial measures provided by other companies. Aptar's management believes these non-GAAP financial measures provide useful information to our investors because they allow for a better period over period comparison of operating results by removing the impact of items that, in management's view, do not reflect Aptar's core operating performance. These non-GAAP financial measures also provide investors with certain information used by Aptar's management when making financial and operational decisions. Free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures. We use free cash flow to measure cash flow generated by operations that is available for dividends, share repurchases, acquisitions and debt repayment. We believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial results but should be read in conjunction with the unaudited condensed consolidated statements of income and other information presented herein. A reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is included in the accompanying tables. Our outlook is provided on a non-GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of the company's routine activities, such as restructuring and acquisition costs. This press release contains forward-looking statements, including certain statements set forth under the 'Outlook' section of this press release. Words such as 'expects,' 'anticipates,' 'believes,' 'estimates,' 'future,' 'potential,' 'continues' and other similar expressions or future or conditional verbs such as 'will,' 'should,' 'would' and 'could' are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: geopolitical conflicts worldwide including the invasion of Ukraine by the Russian military and the resulting indirect impact on demand from our customers selling their products into these countries, as well as rising input costs and certain supply chain disruptions; cybersecurity threats against our systems and/or service providers that could impact our networks and reporting systems; the availability of raw materials and components (particularly from sole sourced suppliers for some of our Pharma solutions) as well as the financial viability of these suppliers; our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights; the outcome of any legal proceeding that has been or may be instituted against us and others;lower demand and asset utilization due to an economic recession either globally or in key markets we operate within; economic conditions worldwide, including inflationary conditions and potential deflationary conditions in other regions we rely on for growth; competition, including technological advances; significant tariffs and other restrictions on foreign imports imposed by the U.S. and related countermeasures taken by impacted foreign countries; the execution of our fixed cost reduction initiatives, including our optimization initiative; our ability to successfully implement facility expansions and new facility projects; fluctuations in the cost of materials, components, transportation cost as a result of supply chain disruptions and labor shortages, and other input costs; significant fluctuations in foreign currency exchange rates or our effective tax rate; the impact of tax reform legislation, changes in tax rates and other tax-related events or transactions that could impact our effective tax rate; financial conditions of customers and suppliers; consolidations within our customer or supplier bases; changes in customer and/or consumer spending levels; loss of one or more key accounts; our ability to offset inflationary impacts with cost containment, productivity initiatives and price increases; changes in capital availability or cost, including rising interest rates; volatility of global credit markets; our ability to identify potential new acquisitions and to successfully acquire and integrate such operations, including the successful integration of the businesses we have acquired; our ability to build out acquired businesses and integrate the product/service offerings of the acquired entities into our existing product/service portfolio; direct or indirect consequences of acts of war, terrorism or social unrest; the impact of natural disasters and other weather-related occurrences; fiscal and monetary policies and other regulations; changes, difficulties or failures in complying with government regulation, including FDA or similar foreign governmental authorities; changing regulations or market conditions regarding environmental sustainability; our ability to retain key members of management and manage labor costs; work stoppages due to labor disputes; our ability to meet future cash flow estimates to support our goodwill impairment testing; the demand for existing and new products; the success of our customers' products, particularly in the pharmaceutical industry; our ability to manage worldwide customer launches of complex technical products, particularly in developing markets; difficulties in product development and uncertainties related to the timing or outcome of product development; significant product liability claims; and other risks associated with our operations. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in our Form 10-K and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. AptarGroup, Inc. Condensed Consolidated Financial Statements (Unaudited) (In Thousands, Except Per Share Data) Consolidated Statements of Income Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net Sales $ 966,009 $ 910,063 $ 1,853,314 $ 1,825,511 Cost of Sales (exclusive of depreciation and amortization shown below) 598,994 567,440 1,149,885 1,150,196 Selling, Research & Development and Administrative 151,139 149,330 306,416 302,110 Depreciation and Amortization 69,904 64,968 135,551 129,317 Restructuring Initiatives 1,579 2,315 3,621 5,795 Operating Income 144,393 126,010 257,841 238,093 Other Income (Expense): Interest Expense (10,850 ) (10,061 ) (22,201 ) (20,236 ) Interest Income 1,880 3,102 4,694 6,000 Net Investment Gain (Loss) 2,102 (140 ) 1,006 452 Equity in Results of Affiliates 2,309 130 4,395 (91 ) Miscellaneous Income, net (120 ) (795 ) (6 ) (1,654 ) Income before Income Taxes 139,714 118,246 245,729 222,564 Provision for Income Taxes 27,982 27,788 55,334 49,173 Net Income $ 111,732 $ 90,458 $ 190,395 $ 173,391 Net (Gain) Loss Attributable to Noncontrolling Interests (12 ) (4 ) 123 167 Net Income Attributable to AptarGroup, Inc. $ 111,720 $ 90,454 $ 190,518 $ 173,558 Net Income Attributable to AptarGroup, Inc. per Common Share: Basic $ 1.69 $ 1.36 $ 2.88 $ 2.62 Diluted $ 1.67 $ 1.34 $ 2.83 $ 2.57 Average Numbers of Shares Outstanding: Basic 65,995 66,312 66,132 66,188 Diluted 67,048 67,575 67,262 67,509 Expand AptarGroup, Inc. Condensed Consolidated Financial Statements (Unaudited) (continued) ($ In Thousands) Consolidated Balance Sheets June 30, 2025 December 31, 2024 ASSETS Cash and Equivalents $ 161,728 $ 223,844 Short-term Investments 8,037 2,337 Accounts and Notes Receivable, Net 800,225 658,057 Inventories 527,421 461,807 Prepaid and Other 165,609 132,338 Total Current Assets 1,663,020 1,478,383 Property, Plant and Equipment, Net 1,584,533 1,447,150 Goodwill 996,489 936,256 Other Assets 621,339 570,489 Total Assets $ 4,865,381 $ 4,432,278 LIABILITIES AND STOCKHOLDERS' EQUITY Short-Term Obligations $ 551,523 $ 338,285 Accounts Payable, Accrued and Other Liabilities 817,361 729,996 Total Current Liabilities 1,368,884 1,068,281 Long-Term Obligations 535,054 688,066 Deferred Liabilities and Other 243,629 190,007 Total Liabilities 2,147,567 1,946,354 AptarGroup, Inc. Stockholders' Equity 2,700,122 2,471,888 Noncontrolling Interests in Subsidiaries 17,692 14,036 Total Stockholders' Equity 2,717,814 2,485,924 Total Liabilities and Stockholders' Equity $ 4,865,381 $ 4,432,278 Expand AptarGroup, Inc. Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) Three Months Ended June 30, 2025 Consolidated Aptar Pharma Aptar Beauty Aptar Closures Corporate & Other Net Interest Net Sales $ 966,009 $ 442,589 $ 334,849 $ 188,571 $ — $ — Reported net income $ 111,732 Reported income taxes 27,982 Reported income before income taxes 139,714 122,594 24,628 17,546 (16,084 ) (8,970 ) Adjustments: Restructuring initiatives 1,579 68 626 890 (5 ) Net investment gain (2,102 ) — — — (2,102 ) Transaction costs related to acquisitions 344 — 344 — — Adjusted earnings before income taxes 139,535 122,662 25,598 18,436 (18,191 ) (8,970 ) Interest expense 10,850 10,850 Interest income (1,880 ) (1,880 ) Adjusted earnings before net interest and taxes (Adjusted EBIT) 148,505 122,662 25,598 18,436 (18,191 ) — Depreciation and amortization 69,904 34,169 21,475 13,447 813 Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) $ 218,409 $ 156,831 $ 47,073 $ 31,883 $ (17,378 ) $ — Reported net income margins (Reported net income / Reported Net Sales) 11.6 % Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) 22.6 % 35.4 % 14.1 % 16.9 % Expand Three Months Ended June 30, 2024 Consolidated Aptar Pharma Aptar Beauty Aptar Closures Corporate & Other Net Interest Net Sales $ 910,063 $ 414,533 $ 321,487 $ 174,043 $ — $ — Reported net income $ 90,458 Reported income taxes 27,788 Reported income before income taxes 118,246 111,814 22,773 11,971 (21,353 ) (6,959 ) Adjustments: Restructuring initiatives 2,315 65 1,199 893 158 Net investment loss 140 — — — 140 Transaction costs related to acquisitions 140 — 140 — — Adjusted earnings before income taxes 120,841 111,879 24,112 12,864 (21,055 ) (6,959 ) Interest expense 10,061 10,061 Interest income (3,102 ) (3,102 ) Adjusted earnings before net interest and taxes (Adjusted EBIT) 127,800 111,879 24,112 12,864 (21,055 ) — Depreciation and amortization 64,968 29,609 20,526 14,254 579 Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) $ 192,768 $ 141,488 $ 44,638 $ 27,118 $ (20,476 ) $ — Reported net income margins (Reported net income / Reported Net Sales) 9.9 % Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) 21.2 % 34.1 % 13.9 % 15.6 % Expand AptarGroup, Inc. Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) Six Months Ended June 30, 2025 Consolidated Aptar Pharma Aptar Beauty Aptar Closures Corporate & Other Net Interest Net Sales $ 1,853,314 $ 852,056 $ 640,556 $ 360,702 $ — $ — Reported net income $ 190,395 Reported income taxes 55,334 Reported income before income taxes 245,729 233,706 41,309 29,879 (41,658 ) (17,507 ) Adjustments: Restructuring initiatives 3,621 258 1,021 2,242 100 Net investment gain (1,006 ) — — — (1,006 ) Transaction costs related to acquisitions 344 — 344 — — Adjusted earnings before income taxes 248,688 233,964 42,674 32,121 (42,564 ) (17,507 ) Interest expense 22,201 22,201 Interest income (4,694 ) (4,694 ) Adjusted earnings before net interest and taxes (Adjusted EBIT) 266,195 233,964 42,674 32,121 (42,564 ) — Depreciation and amortization 135,551 65,317 41,537 27,022 1,675 Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) $ 401,746 $ 299,281 $ 84,211 $ 59,143 $ (40,889 ) $ — Reported net income margins (Reported net income / Reported Net Sales) 10.3 % Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) 21.7 % 35.1 % 13.1 % 16.4 % Expand Six Months Ended June 30, 2024 Consolidated Aptar Pharma Aptar Beauty Aptar Closures Corporate & Other Net Interest Net Sales $ 1,825,511 $ 821,826 $ 648,807 $ 354,878 $ — $ — Reported net income $ 173,391 Reported income taxes 49,173 Reported income before income taxes 222,564 215,166 39,969 24,841 (43,176 ) (14,236 ) Adjustments: Restructuring initiatives 5,795 89 3,909 1,653 144 Net investment gain (452 ) — — — (452 ) Transaction costs related to acquisitions 140 — 140 — — Adjusted earnings before income taxes 228,047 215,255 44,018 26,494 (43,484 ) (14,236 ) Interest expense 20,236 20,236 Interest income (6,000 ) (6,000 ) Adjusted earnings before net interest and taxes (Adjusted EBIT) 242,283 215,255 44,018 26,494 (43,484 ) — Depreciation and amortization 129,317 58,411 41,754 27,785 1,367 — Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) $ 371,600 $ 273,666 $ 85,772 $ 54,279 $ (42,117 ) $ — Reported net income margins (Reported net income / Reported Net Sales) 9.5 % Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) 20.4 % 33.3 % 13.2 % 15.3 % Expand AptarGroup, Inc. Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited) (In Thousands, Except Per Share Data) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Income before Income Taxes $ 139,714 $ 118,246 $ 245,729 $ 222,564 Adjustments: Restructuring initiatives 1,579 2,315 3,621 5,795 Net investment (gain) loss (2,102 ) 140 (1,006 ) (452 ) Transaction costs related to acquisitions 344 140 344 140 Foreign currency effects (1) 3,665 358 Adjusted Earnings before Income Taxes $ 139,535 $ 124,506 $ 248,688 $ 228,405 Provision for Income Taxes $ 27,982 $ 27,788 $ 55,334 $ 49,173 Adjustments: Restructuring initiatives 421 567 927 1,458 Net investment (gain) loss (515 ) 34 (246 ) (111 ) Transaction costs related to acquisitions 86 35 86 35 Foreign currency effects (1) 861 79 Adjusted Provision for Income Taxes $ 27,974 $ 29,285 $ 56,101 $ 50,634 Net (Gain) Loss Attributable to Noncontrolling Interests $ (12 ) $ (4 ) $ 123 $ 167 Net Income Attributable to AptarGroup, Inc. $ 111,720 $ 90,454 $ 190,518 $ 173,558 Adjustments: Restructuring initiatives 1,158 1,748 2,694 4,337 Net investment (gain) loss (1,587 ) 106 (760 ) (341 ) Transaction costs related to acquisitions 258 105 258 105 Foreign currency effects (1) 2,804 279 Adjusted Net Income Attributable to AptarGroup, Inc. $ 111,549 $ 95,217 $ 192,710 $ 177,938 Average Number of Diluted Shares Outstanding 67,048 67,575 67,262 67,509 Net Income Attributable to AptarGroup, Inc. Per Diluted Share $ 1.67 $ 1.34 $ 2.83 $ 2.57 Adjustments: Restructuring initiatives 0.02 0.03 0.04 0.06 Net investment (gain) loss (0.03 ) — (0.01 ) — Transaction costs related to acquisitions — — — — Foreign currency effects (1) 0.04 0.01 Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share $ 1.66 $ 1.41 $ 2.86 $ 2.64 (1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current period foreign currency exchange rates. Expand AptarGroup, Inc. Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited) (In Thousands) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net Cash Provided by Operations $ 125,958 $ 143,579 $ 208,700 $ 235,912 Capital Expenditures (63,425 ) (68,205 ) (120,287 ) (143,866 ) Proceeds from Government Grants 3,308 — 3,308 — Free Cash Flow $ 65,841 $ 75,374 $ 91,721 $ 92,046 Expand AptarGroup, Inc. Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited) (In Thousands, Except Per Share Data) Three Months Ending September 30, Expected 2025 2024 Income before Income Taxes $ 131,131 Adjustments: Restructuring initiatives 3,864 Curtailment gain related to restructuring initiatives (1,851 ) Net investment gain (1,043 ) Transaction costs related to acquisitions — Foreign currency effects (1) 7,045 Adjusted Earnings before Income Taxes $ 139,146 Provision for Income Taxes $ 31,209 Adjustments: Restructuring initiatives 1,013 Curtailment gain related to restructuring initiatives (478 ) Net investment gain (255 ) Transaction costs related to acquisitions — Foreign currency effects (1) 1,677 Adjusted Provision for Income Taxes $ 33,166 Net Loss Attributable to Noncontrolling Interests $ 117 Net Income Attributable to AptarGroup, Inc. $ 100,039 Adjustments: Restructuring initiatives 2,851 Curtailment gain related to restructuring initiatives (1,373 ) Net investment gain (788 ) Transaction costs related to acquisitions — Foreign currency effects (1) 5,368 Adjusted Net Income Attributable to AptarGroup, Inc. $ 106,097 Average Number of Diluted Shares Outstanding 67,716 Net Income Attributable to AptarGroup, Inc. Per Diluted Share (3) $ 1.48 Adjustments: Restructuring initiatives 0.04 Curtailment gain related to restructuring initiatives (0.02 ) Net investment gain (0.01 ) Transaction costs related to acquisitions — Foreign currency effects (1) 0.05 Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share (2) $1.53 - $1.61 $ 1.54 (1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current spot rates for all applicable foreign currency exchange rates. (2) AptarGroup's expected earnings per share range for the third quarter of 2025, excluding any restructuring expenses, acquisition costs and changes in fair value of equity investments, is based on an effective tax rate range of 20.5% to 22.5%. This tax rate range compares to our third quarter of 2024 effective tax rate of 23.8% on reported earnings and adjusted earnings per share. Expand
Yahoo
25-07-2025
- Business
- Yahoo
AptarGroup (ATR): The Unsung Hero of Reliable Dividend Growth
AptarGroup, Inc. (NYSE:ATR) was recently included on our list of Dividend Champion vs Aristocrats: 12 Under the Radar Stocks to Buy. A close-up of a technician inspecting and testing a dispensing closure component. AptarGroup, Inc. (NYSE:ATR) has a global presence, generating about half of its revenue in Europe and 33% in North America. The company has completed nearly two dozen acquisitions, investments, and partnerships since 2016, expanding its reach and broadening its portfolio. The stock has surged by nearly 5% since the start of 2025. AptarGroup, Inc. (NYSE:ATR) reported mixed earnings in the first quarter of 2025. The company posted revenue of $887 million, which showed a 3% decline from the same period last year. Pharma's proprietary drug delivery systems delivered a 2% increase in reported sales and a 4% rise in core sales for the quarter. The company experienced heightened demand for its dosing, dispensing, and protection technologies across various segments, including treatments for central nervous system disorders, emergency medications, weight and diabetes management, and applications in food, beverage, and personal care. AptarGroup, Inc. (NYSE:ATR) also posted a strong cash position during the quarter. The company's operating cash flow was $82.7 million, and its free cash flow amounted to $25.8 million. It also returned $110 million to shareholders through dividends, which makes it one of the best stocks on our dividend champions list. The company has raised its payouts for 31 years in a row. Currently, it pays a quarterly dividend of $0.45 per share and has a dividend yield of 1.11%, as of July 23. While we acknowledge the potential of ATR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Sign in to access your portfolio
Business Insider
09-07-2025
- Business
- Business Insider
AptarGroup debuts dual-active technology to control moisture, oxygen
AptarGroup (ATR) announced it has developed a dual-active material science technology engineered to simultaneously control moisture and oxygen. The company stated this technology is designed to provide a singular solution to address degradation drivers for pharmaceutical drugs, including oral solid dose GLP-1 medications, and medical devices. The new solution marks a breakthrough in the pharmaceutical industry and extends Aptar's 3-Phase Activ-Polymer technology into new use cases. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Yahoo
02-07-2025
- Business
- Yahoo
Is AptarGroup, Inc.'s (NYSE:ATR) Latest Stock Performance Being Led By Its Strong Fundamentals?
AptarGroup's (NYSE:ATR) stock is up by 5.6% over the past three months. Since the market usually pay for a company's long-term financial health, we decided to study the company's fundamentals to see if they could be influencing the market. Specifically, we decided to study AptarGroup's ROE in this article. Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. ROE can be calculated by using the formula: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for AptarGroup is: 14% = US$370m ÷ US$2.6b (Based on the trailing twelve months to March 2025). The 'return' is the yearly profit. Another way to think of that is that for every $1 worth of equity, the company was able to earn $0.14 in profit. Check out our latest analysis for AptarGroup We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don't share these attributes. To begin with, AptarGroup seems to have a respectable ROE. And on comparing with the industry, we found that the the average industry ROE is similar at 14%. This probably goes some way in explaining AptarGroup's moderate 11% growth over the past five years amongst other factors. Next, on comparing with the industry net income growth, we found that AptarGroup's growth is quite high when compared to the industry average growth of 1.4% in the same period, which is great to see. Earnings growth is a huge factor in stock valuation. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. Is ATR fairly valued? This infographic on the company's intrinsic value has everything you need to know. With a three-year median payout ratio of 36% (implying that the company retains 64% of its profits), it seems that AptarGroup is reinvesting efficiently in a way that it sees respectable amount growth in its earnings and pays a dividend that's well covered. Additionally, AptarGroup has paid dividends over a period of at least ten years which means that the company is pretty serious about sharing its profits with shareholders. Upon studying the latest analysts' consensus data, we found that the company is expected to keep paying out approximately 31% of its profits over the next three years. Accordingly, forecasts suggest that AptarGroup's future ROE will be 13% which is again, similar to the current ROE. On the whole, we feel that AptarGroup's performance has been quite good. Particularly, we like that the company is reinvesting heavily into its business, and at a high rate of return. Unsurprisingly, this has led to an impressive earnings growth. Having said that, the company's earnings growth is expected to slow down, as forecasted in the current analyst estimates. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
24-06-2025
- Business
- Yahoo
Zacks.com featured highlights Agnico Eagle Mines, AptarGroup and VICI Properties
Chicago, IL – June 24, 2025 – The stocks in this week's article are Agnico Eagle Mines Ltd. AEM, AptarGroup, Inc. ATR and VICI Properties Inc. VICI. Earnings growth is essential for any organization, regardless of size, as profitability is vital for survival. To determine earnings, analyze a company's revenues over a specific period and subtract the production costs. Additionally, earnings significantly influence share prices, with earnings expectations playing a major role. On that note, Agnico Eagle Mines Ltd., AptarGroup, Inc. and VICI Properties Inc. are demonstrating impressive earnings growth. Frequently, we have seen a decline in stock prices despite earnings growth, followed by a rally in prices after an earnings decline. This is largely the result of a company's earnings failing to meet market expectations. Earnings estimates reflect analysts' views on factors such as sales growth, product demand, the competitive industry environment, profit margins and cost control. Consequently, earnings estimates are a valuable tool for making investment decisions. They also assist analysts in evaluating cash flow to determine a firm's fair value. Thus, investors should be on the lookout for stocks ready to make a big move. Hence, investors need to buy stocks with a history of earnings growth, and are seeing a rise in quarterly and annual earnings estimates. The above criteria narrowed the universe of around 7,839 stocks to only four. Here are the top three stocks: Agnico Eagle Mines Agnico Eagle Mines, a gold mining company, explores and produces gold, silver, zinc and copper. The company's expected earnings growth rate for the current year is 43%. AEM currently has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. AptarGroup AptarGroup creates various solutions for pharmaceutical, beauty, personal care, home care, and food and beverage markets. The company's expected earnings growth rate for the current year is 4.1%. ATR at present has a Zacks Rank #1. VICI Properties VICI Properties, an S&P 500 real estate investment trust, owns top gaming and entertainment destinations like Caesars Palace, MGM Grand and the Venetian Resort in Las Vegas. The company's expected earnings growth rate for the current year is 4%. VICI presently has a Zacks Rank #2. You can sign up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge. The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out. Click here to sign up for a free trial to the Research Wizard today. For the rest of this Screen of the Week article please visit at: Follow us on Twitter: Join us on Facebook: Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Contact: Jim Giaquinto Company: Phone: 312-265-9268 Email: pr@ Visit: provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agnico Eagle Mines Limited (AEM) : Free Stock Analysis Report AptarGroup, Inc. (ATR) : Free Stock Analysis Report VICI Properties Inc. (VICI) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
